Axtria
Data and analytics platform for pharma sales, marketing, and compliance operations.
On the record
Checkpoint: Visibility into Conexus integration retention and Veeva Vault CRM AI Agents attach rate
The call
Axtria sits on real pharma-compliance know-how but is implementing on platforms that IQVIA, Veeva, and Salesforce now control and are arming with their own AI.
Axtria helps pharmaceutical companies analyze sales data and follow government rules. The company is hard to replace because it knows healthcare regulations deeply and has built relationships with clients through implementation work, especially after buying a company called Conexus in 2026. However, IQVIA, Veeva, and Salesforce all launched AI tools in the past year that do similar analytics work, and since these rivals control the main software platforms that Axtria's customers already use, they can sell their AI agents directly into those systems. The one thing that could save Axtria is if its implementation services and compliance expertise become so valuable that customers pay extra for them even when they could get basic analytics from their existing software vendors, but right now that is uncertain.
Why
01
AI pressure: IQVIA.ai, Veeva AI Agents, and Salesforce Agentforce Life Sciences. All three launched agents that automate the dashboarding and data-engineering work Axtria bills pharma clients for. Could AI do the core job? Yes, likely.
02
Bigger players: Veeva Systems. Veeva owns the CRM platform Axtria implements on top of, and is adding native AI that could pull implementation work back in-house. Could a giant copy it? Yes, easily.
03
What protects it. Regulatory and GxP compliance expertise plus existing CRM implementation relationships, deepened by the Conexus acquisition.
What would change this call
Whether Axtria's Conexus-driven CRM implementation revenue holds through Q2-Q3 2026 as Veeva rolls out Vault CRM AI Agents. Shows if Veeva is reabsorbing Axtria's implementation revenue into its own platform.
Any audited revenue disclosure (IPO S-1 or new funding round) that resolves the $250M vs $1.1B+ estimate gap. Clarifies Axtria's true scale and whether it can fund competing with IQVIA, Veeva, Salesforce.
Axtria headcount trend past Q1 2026 (currently down 5.8% YoY per Revelio Labs). Indicates whether contraction is stabilizing or accelerating despite fresh Kedaara capital.
Any audited revenue disclosure (IPO S-1 or new funding round) that resolves the $250M vs $1.1B+ estimate gap. Clarifies Axtria's true scale and whether it can fund competing with IQVIA, Veeva, Salesforce.
Axtria headcount trend past Q1 2026 (currently down 5.8% YoY per Revelio Labs). Indicates whether contraction is stabilizing or accelerating despite fresh Kedaara capital.
Key numbers
- $240M Kedaara Capital deal, partly a secondary sale
- Employee count down 5.8% YoY to ~4,171
- Job postings up 60% in 2025 despite headcount decline
Named risks
- Three much larger rivals (IQVIA, Veeva, Salesforce) shipped competing agentic AI into Axtria's core workflows within 12 months.
- Headcount declined 5.8% YoY to 4,171 in Q1 2026 from a 2024 peak, despite fresh capital and M&A.
- Revenue figures unreconciled, ranging from $250M to $1.2B, undermining scale credibility.
- Early investors exited via secondary sale in the September 2025 Kedaara deal, signaling possible ownership instability.
- Axtria lacks a proprietary real-world data asset comparable to IQVIA, relying instead on orchestrating client data.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| IQVIA | losing to | Launched IQVIA.ai with NVIDIA March 2026, dwarfing Axtria at $15.4B FY2024 revenue vs Axtria's disputed scale |
| Veeva Systems | losing to | Shipped Vault CRM AI Agents Dec 2025 to 1,552 customers, controls the platform Axtria's Conexus unit implements on |
| Salesforce | losing to | Agentforce Life Sciences reached GA Oct 2025 with AstraZeneca, Novartis, Takeda, Pfizer as named customers |
| Fractal Analytics | contesting | Direct peer in life sciences data analytics and AI, competing for same client base as of 2026 |
Questions people ask
- Is Axtria profitable in 2026?
- Axtria does not publicly disclose profitability figures. Its India entity reported estimated EBITDA of Rs173.2 Cr on Rs867.5 Cr revenue in FY24, up 28.5percent YoY, but no consolidated global profit figure has been disclosed as of May 2026.
- Could AI replace Axtria's core business?
- Axtria's bespoke data engineering and dashboarding services are exactly the workflow that IQVIA.ai, Veeva AI Agents, and Salesforce Agentforce Life Sciences all launched agentic AI products into between October 2025 and March 2026, directly targeting the analytics work Axtria has traditionally sold.
- Who is Axtria's biggest competitor?
- IQVIA is the largest threat, with roughly $15.4B in FY2024 revenue versus Axtria's disputed $250M to $1.2B range. IQVIA launched IQVIA.ai with NVIDIA in March 2026, while Veeva and Salesforce also shipped competing agentic AI into Axtria's core CRM workflows.
- Is Axtria a safe company to join in 2026?
- Mixed signal. Revelio Labs shows headcount fell 5.8percent YoY to 4,171 employees in Q1 2026 from a 2024 peak of 4,477, even as job postings rose 60percent in 2025 and the company raised $240M from Kedaara Capital in September 2025.
- Who owns Axtria?
- Axtria is privately held and venture/PE backed, founded in 2010 by Jaswinder Chadha and Navdeep Chadha. Kedaara Capital invested $240M in September 2025, partly via secondary sale letting early investors exit, valuing the company near $1B.
- What is Axtria's actual revenue?
- Unclear. CBInsights cites $250M for 2025 while data brokers like ZoomInfo cite $1.16 to 1.2B, an unreconciled 4 to 5x discrepancy as of July 2026. The India subsidiary alone reported Rs867.5 Cr, about $104M, in FY24.
Timeline
- 2026-04-29Axtria and LangChain announce AgentOps AI governance framework for pharma, live in production
- 2026-04-15Axtria acquires Conexus Solutions to add Veeva and Salesforce CRM implementation expertise
- 2026-03IQVIA launches IQVIA.ai agentic platform with NVIDIA
- 2025-12Veeva ships Vault CRM AI Agents to its 1,552 pharma customers
- 2025-10Salesforce Agentforce Life Sciences reaches general availability
- 2025-09-23Kedaara Capital invests $240M in Axtria via secondary sale and buyback
- 2024Axtria employee headcount peaks at 4,477 per Revelio Labs
- 2023-06-30Axtria announces plans to hire 1,000-plus employees across India offices
- 2021-05-12Axtria raises $150M Series E from Bain Capital at up to $1B valuation
- 2010Axtria founded by Jaswinder Chadha and Navdeep Chadha in Berkeley Heights, NJ
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Axtria, LangChain Partnership Advances Governed AI Agents in Life Sciences (2026-04-29)
- Axtria Raises $150 Million From Bain Capital at $1 Billion Value (2021-05-12)
- Kedaara Capital backs AI life sciences company Axtria with $240 million (2025-09-23)
- Valuation, Funding Rounds & Stock Price (2026-04-28)
- Axtria Stock Price, Funding, Valuation, Revenue & Financial Statements (2026-04-14)
- Axtria Financials 2026, Revenue, P&L & Cash Flow (2026-05-28)
- Axtria and LangChain Partner to Govern and Scale AI Agents in Pharma (2026-04-29)
- Management and Employees List
- Axtria Number of Employees 2026
- Company Profile
- Axtria IPO Timeline and Financing Details (2023-11-14)
- Axtria Company Profile